This strategic move underscores the Sun Nuclear commitment to leverage cutting-edge technology to improve treatment outcomes on behalf of our customers.
Oncospace’s AI and machine-learning technologies are designed to develop data-driven, physician-centric solutions that optimize patient outcomes. Since its inception in 2018, Oncospace has launched two main offerings:
“We are excited to welcome Oncospace into the Sun Nuclear family,” said Luis Rivera, Sun Nuclear president and Mirion Medical executive vice president. “By incorporating the Oncospace solutions dependent on AI and machine-learning capabilities, Sun Nuclear is affirming our commitment to drive innovation in radiation therapy. We look forward to the positive impact this will have on our software roadmap.”
By informing actions through harnessing vital information, the Oncospace offerings address the demands of radiation oncology professionals while improving the precision and efficiency of radiation therapy planning, thus enhancing the overall quality of care and outcomes. This acquisition aligns with the Sun Nuclear focus of enhancing the quality and accessibility of radiation therapy, ensuring that patients receive the best possible treatment.
Oncospace software will be featured in Sun Nuclear’s booth at ESTRO 2025, May 2-6, in Vienna, Austria. ESTRO is the annual congress for the European Society for Radiotherapy and Oncology and includes Europe’s largest industry exhibition in radiation oncology.